[go: up one dir, main page]

DK289688A - Ekspression af proapolipoprotein a-i. - Google Patents

Ekspression af proapolipoprotein a-i.

Info

Publication number
DK289688A
DK289688A DK289688A DK289688A DK289688A DK 289688 A DK289688 A DK 289688A DK 289688 A DK289688 A DK 289688A DK 289688 A DK289688 A DK 289688A DK 289688 A DK289688 A DK 289688A
Authority
DK
Denmark
Prior art keywords
proapolipoprotein
sequence
expression vectors
dna sequences
expression
Prior art date
Application number
DK289688A
Other languages
English (en)
Other versions
DK175686B1 (da
DK289688D0 (da
Inventor
Alex Bollen
Jean Gobert
Ernst Wuelfert
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of DK289688D0 publication Critical patent/DK289688D0/da
Publication of DK289688A publication Critical patent/DK289688A/da
Application granted granted Critical
Publication of DK175686B1 publication Critical patent/DK175686B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK198802896A 1987-05-28 1988-05-27 Rekombinant DNA-sekvens for humant proapolipoprotein A-I, klonings- og ekspressionsvektor indeholdende sekvensen............. DK175686B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878712540A GB8712540D0 (en) 1987-05-28 1987-05-28 Expression of human proapolipoprotein a-i
GB8712540 1987-05-28

Publications (3)

Publication Number Publication Date
DK289688D0 DK289688D0 (da) 1988-05-27
DK289688A true DK289688A (da) 1988-11-29
DK175686B1 DK175686B1 (da) 2005-01-17

Family

ID=10618034

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198802896A DK175686B1 (da) 1987-05-28 1988-05-27 Rekombinant DNA-sekvens for humant proapolipoprotein A-I, klonings- og ekspressionsvektor indeholdende sekvensen.............

Country Status (33)

Country Link
US (1) US5059528A (da)
EP (1) EP0293357B1 (da)
JP (1) JP2634193B2 (da)
KR (1) KR970000808B1 (da)
CN (1) CN1031892C (da)
AT (1) ATE89006T1 (da)
AU (1) AU615654B2 (da)
CA (1) CA1323851C (da)
CY (1) CY1809A (da)
CZ (1) CZ283648B6 (da)
DD (1) DD291093A5 (da)
DE (1) DE3880739T2 (da)
DK (1) DK175686B1 (da)
EG (1) EG19101A (da)
ES (1) ES2054878T3 (da)
FI (1) FI100056B (da)
GB (1) GB8712540D0 (da)
HK (1) HK137794A (da)
HU (1) HU204562B (da)
IE (1) IE62422B1 (da)
IL (1) IL86480A (da)
LT (1) LT3600B (da)
LV (1) LV5288A3 (da)
NO (1) NO179253C (da)
NZ (1) NZ224808A (da)
PL (1) PL158064B1 (da)
PT (1) PT87562B (da)
RU (1) RU2009198C1 (da)
SG (1) SG131594G (da)
SK (1) SK279166B6 (da)
SU (1) SU1834904A3 (da)
UA (1) UA19765A (da)
ZA (1) ZA883824B (da)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JP2606228B2 (ja) * 1987-09-18 1997-04-30 三菱化学株式会社 ヒトプロアポリポプロテインａ−ｉ様蛋白の産生法
DE68917379T2 (de) * 1988-05-31 1994-12-01 Mitsubishi Chem Ind Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind.
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
ES2109336T3 (es) * 1990-11-26 1998-01-16 Genetics Inst Expresion de pace en celulas huesped y metodos de utilizacion de la misma.
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
DK0559795T3 (da) * 1990-11-30 1996-01-29 Monoclonetics Int Fremgangsmåder til diagnosticering af kroniske smerter i lænderegionen og halshvrivelsøjlen
GB9508618D0 (en) * 1995-04-28 1995-06-14 Applied Research Systems Therapeutic protein
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5994061A (en) * 1995-09-29 1999-11-30 Queen's University At Kingston DNA constructs and methods for screening for increased expression of human apo AI gene
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
KR100330355B1 (ko) * 1999-06-04 2002-04-01 장인순 회전유동발생 날개를 가진 덕트형 핵연료 집합체 지지격자
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
EP1341919A2 (en) * 2000-12-12 2003-09-10 Lexicon Genetics Incorporated Novel human kinases and uses thereof
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US7427662B2 (en) * 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
EP1917278A2 (en) * 2005-08-26 2008-05-07 Cerenis Therapeutics Holding SA Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
US20080293102A1 (en) * 2007-02-28 2008-11-27 Cerenis Therapeutics Holding, S.A. Compositions and methods for producing apolipoprotein
RU2604489C2 (ru) * 2008-10-03 2016-12-10 КьюРНА,Инк.,US Лечение заболеваний, связанных с аполипопротеином-а1, путем ингибирования природного антисмыслового транскрипта аполипопротеина-а1
CN111909020A (zh) 2008-11-10 2020-11-10 阿布特斯生物制药公司 用于递送治疗剂的脂质和组合物
US20120101148A1 (en) 2009-01-29 2012-04-26 Alnylam Pharmaceuticals, Inc. lipid formulation
CA2754043A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
KR20240015723A (ko) 2009-05-05 2024-02-05 알닐람 파마슈티칼스 인코포레이티드 지질 조성물
CN102459596B (zh) 2009-05-06 2016-09-07 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
CA2764609C (en) 2009-06-10 2018-10-02 Alnylam Pharmaceuticals, Inc. Improved cationic lipid of formula i
WO2011020023A2 (en) 2009-08-14 2011-02-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
AU2010328336B2 (en) 2009-12-07 2017-03-02 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
WO2011075656A1 (en) 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
ES3053320T3 (en) 2010-06-03 2026-01-21 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US9339513B2 (en) 2010-11-09 2016-05-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP3202760B1 (en) 2011-01-11 2019-08-21 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
CN103443123B (zh) 2011-02-07 2020-05-29 塞勒尼斯医疗控股公司 脂蛋白复合物及其制备和用途
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
US9610324B2 (en) * 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
DK2991656T3 (da) * 2013-05-01 2020-03-23 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
MX2016014306A (es) 2014-05-02 2017-06-12 Cerenis Therapeutics Holding Sa Marcadores para terapia con lipoproteinas de alta densidad (hdl).
CN108473990A (zh) * 2016-10-27 2018-08-31 中国科学院微生物研究所 氨基酸衰减子的改造方法及其在生产中的应用
TW201919686A (zh) 2017-08-10 2019-06-01 法商塞勒尼斯醫療控股公司 脫輔基子(apomers)
EP3668600B1 (en) 2017-08-10 2024-05-15 Abionyx Pharma SA Cargomers
US11461863B2 (en) 2018-08-24 2022-10-04 Bright Marbles, Inc. Idea assessment and landscape mapping
US11164065B2 (en) 2018-08-24 2021-11-02 Bright Marbles, Inc. Ideation virtual assistant tools
US11081113B2 (en) 2018-08-24 2021-08-03 Bright Marbles, Inc. Idea scoring for creativity tool selection
US11189267B2 (en) 2018-08-24 2021-11-30 Bright Marbles, Inc. Intelligence-driven virtual assistant for automated idea documentation
JP2023522889A (ja) 2020-04-16 2023-06-01 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、急性病態を治療するための方法
JP2023543498A (ja) 2020-10-01 2023-10-16 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
CN117479834A (zh) 2021-04-15 2024-01-30 阿比奥尼克斯制药公司 基于脂质结合蛋白的复合物在器官保存溶液中的用途
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
IL316110A (en) 2022-04-06 2024-12-01 Abionyx Pharma Sa Methods for treating eye diseases using complexes based on fat-binding protein
CA3258787A1 (en) 2022-06-10 2023-12-14 Stanislas FAGUER METHODS OF TREATMENT OF HYPERINFLAMMATORY DISEASES USING LIPID-BINDING PROTEIN COMPLEXES
EP4536269A2 (en) 2022-06-10 2025-04-16 Abionyx Pharma SA Methods for treating acute conditions using lipid binding protein-based complexes
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JPS6198998A (ja) 1984-10-18 1986-05-17 Matsushita Electric Ind Co Ltd 電動送風機
BE901119A (fr) 1984-11-23 1985-03-15 Wallone Region Procede de preparation de plasmides vecteurs capables de transformer un hote bacterien escherichia coli et d'y promouvoir et controler l'expression d'un adn heterologue.
ATE89314T1 (de) 1985-02-13 1993-05-15 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
AU6522486A (en) 1985-10-04 1987-04-24 Biotechnology Research Partners Limited Recombinant apolipoproteins and methods
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
AU8273987A (en) * 1986-10-29 1988-05-25 Biotechnology Research Partners Limited Apoai-ciii-aiv, apoaii apob , apoci, and ldl receptor polymorphisms for genetic fingerprinting and predictive of atherosclerosis

Also Published As

Publication number Publication date
ZA883824B (en) 1989-02-22
DE3880739D1 (de) 1993-06-09
EP0293357A1 (fr) 1988-11-30
FI882456A0 (fi) 1988-05-25
JPS6416589A (en) 1989-01-20
AU615654B2 (en) 1991-10-10
AU1672388A (en) 1988-12-01
IL86480A0 (en) 1988-11-15
DE3880739T2 (de) 1993-08-19
NZ224808A (en) 1990-01-29
LT3600B (en) 1995-12-27
SK363888A3 (en) 1998-07-08
EG19101A (en) 1994-09-29
FI882456L (fi) 1988-11-29
DD291093A5 (de) 1991-06-20
PL272698A1 (en) 1989-03-06
NO179253C (no) 1996-09-04
LTIP828A (en) 1995-02-27
EP0293357B1 (fr) 1993-05-05
HU204562B (en) 1992-01-28
CZ283648B6 (cs) 1998-05-13
US5059528A (en) 1991-10-22
NO179253B (no) 1996-05-28
CN88103118A (zh) 1988-12-14
NO882341L (no) 1988-11-29
HK137794A (en) 1994-12-16
DK175686B1 (da) 2005-01-17
ES2054878T3 (es) 1994-08-16
DK289688D0 (da) 1988-05-27
GB8712540D0 (en) 1987-07-01
CN1031892C (zh) 1996-05-29
ATE89006T1 (de) 1993-05-15
CZ363888A3 (cs) 1998-02-18
PL158064B1 (pl) 1992-07-31
RU2009198C1 (ru) 1994-03-15
NO882341D0 (no) 1988-05-27
IL86480A (en) 1992-08-18
PT87562A (pt) 1989-05-31
PT87562B (pt) 1992-09-30
SU1834904A3 (ru) 1993-08-15
IE62422B1 (en) 1995-02-08
LV5288A3 (lv) 1993-10-10
SG131594G (en) 1995-01-13
UA19765A (uk) 1997-12-25
CY1809A (en) 1995-10-20
KR880014110A (ko) 1988-12-22
JP2634193B2 (ja) 1997-07-23
CA1323851C (en) 1993-11-02
SK279166B6 (sk) 1998-07-08
IE881597L (en) 1988-11-28
HUT47153A (en) 1989-01-30
KR970000808B1 (en) 1997-01-20
FI100056B (fi) 1997-09-15

Similar Documents

Publication Publication Date Title
DK289688A (da) Ekspression af proapolipoprotein a-i.
ES8705467A1 (es) Un procedimiento para producir la proteina apoacuorina
ES2059354T3 (es) Un metodo para producir un polipeptido.
NO940736D0 (no) DNA sekvenser som koder for gelonin polypeptid
NO177570B (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
NO930428L (no) Proteinstrukturen til plantetoksingelonin
FI961202A0 (fi) Grb3-3-geeni, sen variantteja ja niiden käyttöjä
ATE166390T1 (de) Anti-katze immundefiziensvirus (fiv) impfstoffe
ATE43139T1 (de) Klonierungs- und expressionsvektoren fuer gammainterferon, transformierte bakterien und verfahren zur herstellung von gamma-interferon.
DK27097A (da) Minactivin og fremgangsmåde til fremstilling deraf
DE3856392D1 (de) Klonierung von Malaria-spezifischen DNA-Sequenzen:Isolierung des Gens für das 140 kd Protein
DE69636737D1 (de) Neues immunoregulatorisches protein lst-1

Legal Events

Date Code Title Description
PUP Patent expired